Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 2,949,911 |
|
|||||
| News | - | ||||||
| Day High | 7.53 | Low High |
|||||
| Day Low | 7.01 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.48 | 6.84% | 7.50 | 18:59:39 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.04 | 7.01 | 7.53 | 7.51 | 7.02 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 20,222 | 2,949,911 | US$ 7.27 | US$ 21,438,560 | - | 2.09 - 14.84 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:39 | 1 | US$ 7.50 | USD |
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 404.58M | 53.73M | - | 426k | -88.45M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.41 | 7.53 | 6.77 | 7.03 | 2,052,444 | 0.09 | 1.21% |
| 1 Month | 7.41 | 9.50 | 6.77 | 7.70 | 2,738,317 | 0.09 | 1.21% |
| 3 Months | 10.14 | 11.50 | 6.282 | 8.46 | 3,431,382 | -2.64 | -26.04% |
| 6 Months | 3.17 | 14.84 | 3.16 | 8.10 | 8,088,309 | 4.33 | 136.59% |
| 1 Year | 4.03 | 14.84 | 2.09 | 7.33 | 4,750,571 | 3.47 | 86.10% |
| 3 Years | 12.70 | 23.49 | 2.09 | 8.79 | 2,618,778 | -5.20 | -40.94% |
| 5 Years | 2.42 | 35.10 | 1.45 | 10.01 | 2,188,801 | 5.08 | 209.92% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
